Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU
0
Authors
Yoshitaka Honma
Yoshitaka Honma•Nobuya Monden•Yuichiro Tada
Published
June 28, 2024
Abstract
To assess efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)-positive, unresectable or recurrent/metastatic salivary gland carcinoma (URM-SGC).
